Document is current

Article History

Received: 13 July 2024

Accepted: 12 November 2024

First Online: 18 November 2024

Declarations

:

: The trial design was retrospectively registered study performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Nagoya University Graduate School of Medicine (approval: 2020 − 0287). Because of retrospective design, the requirement to obtain informed consent was waived according to the ethical guidelines for life sciences and medical research involving human subjects of Japan, which was approved by institutional review boards of each participating institutions.

: Not applicable.

: J Koyama has a patent JP2022-043291 pending. M Morise receives lecture fees from Taiho, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Chugai, Astra Zeneca, Ono, Pfizer, and MSD; is the principal investigator of clinical trials initiated by Chugai, Astra Zeneca, Ono, Pfizer, Merck Serono, Kissei, Taiho, and Novartis; and receives research grants as an investigator to initiate clinical trials for Boehringer Ingelheim and Eli Lilly outside of the submitted work. In addition, M Morise has a patent JP2022-043291 pending; T Furukawa has a patent JP2022-043291 pending; and H Yokota has a patent JP2022-043291 pending. Y Kondoh serves as a consultant to Asahi Kasei, Healios, Shionogi, Boehringer Ingelheim, Janssen, Chugai, and Taiho; received lecture fees from Asahi Kasei, Shionogi, Boehringer Ingelheim, Astra Zeneca, Eisai, Janssen, Bristol Myers Squibb, KYORIN, Mitsubishi Tanabe, Novartis, and Teijin outside of the submitted work. N Hashimoto reports research grants from Boehringer Ingelheim and non-financial support from Astra Zeneca, Glaxo Smith Kline, Novartis, and Boehringer Ingelheim outside of the submitted work. All remaining authors have nothing to disclose.